In CKD patients, the prevalence of resistant hypertension and abnormal BP profiles is also higher and requires investigation through 24 h ABPM and targeted pathophysiological treatment, i.e., optimizing diuretic regimens in volume excess assessment, renin–angiotensin–aldosterone system blockade in hyperactive states, or beta-/alpha-blockade in the presence of clues of sympathetic nervous system mediation [36]. The gene discussed is REN; the disease is Hypertension resistant to conventional therapy.